

SWOG Plenary I
Translational Medicine
*Science as the Foundation for Rapid and
Meaningful Advances in Oncology*

Lee M. Ellis, MD

SWOG Vice Chair, Translational Medicine

Departments of Surgical Oncology and Molecular & Cellular Oncology

UT MD Anderson Cancer Center

Thanks to James Rae, PhD (AKA J.R.)

SWOG Executive Officer, Translational Medicine

Presenter Disclosure Information

Lee Ellis, MD: Consultant for Genentech/Roche

Luiz Diaz, Jr., MD: Consultant for Merck, PGDx, and Cell Design Laboratories. Research grant from Merck. Stock/Shareholder in PGDx and Papgene. Board member of PGDx.

Elaine R. Mardis, PhD: No Disclosures

Nilsa C. Ramirez, MD, FCAP: No Disclosures

Quick Overview of Translational Medicine at SWOG

- The vast majority of work is done within each committee: thanks to all for your commitment and expertise

- Mini-retreats

- Immuno-Oncology Biomarker Mini-retreat Spring 2017

Thanks to NCI, The Hope Foundation, and ITSC Partners for support on innumerable initiatives! *And you!*

- CSHLs - Summer 2017, 16 SWOG members attended

- JAX - June 27-29, 2018, Bar Harbor, Maine

- Hope Foundation Awards
- NCI Correlative Sciences Committee and Navigator update
- CIMAC/UO1 announcement

ITSC Workshop, Bar Harbor ME

June 27-29 2018

- Nominations requested January 2018
- Participants selected March 2018
- Pilot proposal letters of intent due July 2018
- Full application due September 2018
- Award start date March 1, 2019

Funding: The Hope Foundation; U10CA180944; JAX; CSHL



Pilot Project Awards 2017 That Emanated from Collaborations at ITSC Workshop Were Determined Yesterday & Will Be Announced Soon

- Generous support of The Hope Foundation
- U01CA180994 – Drs. Tuveson, Liu, and Baker, PIs
- The Jackson Laboratory
- Cold Spring Harbor Laboratory

THE HOPE FOUNDATION

Because answers to cancers come from clinical trials

SWOG Early Exploration and Development (SEED) Fund	Up to \$50,000 – Funding preliminary research that will translate to clinical trials or trial-associated projects; 1 or 2-year projects	Next deadline December 1, 2017
Latest SEED Grant Recipients (July 2017 Round)	Uma Borate, MD, MS Oregon Health & Science University “Identification of AML Patients with Germline Gene Mutations that Predispose to Myeloid Malignancies to Enhance Early Detection of Transformation Risk to AML in Affected Individuals with Familial Mutations” Joshua Meeks, MD, PhD Northwestern University Feinberg School of Medicine “Development of a Molecular Risk Stratification Tool for High-Risk Non-Muscle Invasive Bladder Cancer”	

SWOG Impact Award Program	Up to \$250,000 – Mechanism for translating scientific discovery to patient care; intended to encourage innovative approaches; 1 or 2-year projects	Next deadline March 1, 2018
Latest Impact Award Recipient (September 2017 Round)	Irene Tami-Maury, DMD, MSc, DrPHr UT MD Anderson Cancer Center “Project STOP, SWOG Tobacco program for Oncology Practice”	

All funding opportunities: thehopefoundation.org/research-funding

NCTN Correlative Sciences Committee and Navigator

Here's information for you to share from the Navigator expert, Grace Mishkin:

- The Navigator pilot will begin this November. We are currently seeking investigators who are developing translational science proposals and would be willing to pilot test the system for us, so please get in touch with the Bank or Group if you are interested.
- The Navigator system will launch in the first quarter of 2018. The SWOG bank and stats staff have been doing great work to get trials loaded in the Navigator IT system for the initial launch. NCI will be sending additional updates as the launch approaches.

Proposal Submission Form

Proposal for use of NCTN Clinical Trial Biospecimens

The biospecimen collections developed from cancer clinical trials conducted by the National Cancer Institute's (NCI's) National Clinical Trials Network (NCTN) are highly annotated with carefully collected clinical data, including outcome data. The NCTN Core Correlative Sciences Committee (NCTN-CCSC) is charged with scientific review and prioritization of proposals requesting use of banked, non-reserved biospecimens collected from NCTN clinical trials for use in correlative science studies. The NCTN-CCSC has oversight for ensuring optimal use of these irreplaceable clinical trial biospecimens.

NCINCTN-CCSC@mail.nih.gov

Cancer Immune Monitoring and Analysis Centers (CIMACs) Cancer Immunologic Data Commons (CIDC)

- **Why CIMAC-CIDC network**
 - To provide a standing, prefunded network of laboratories, along with a common data center, to perform biomarker assays and analysis for NCI-funded, early phase 1/2 clinical trials with immunotherapies, using standardized and state of the art assays
 - Data repository/center for biomarker results from CIMACs will foster a data integration/analysis platform for correlative studies within and across trials
- **Funded under cooperative grant mechanisms (U24)**
 - Current funding limited to early immunotherapy trials (phase I and phase II) under the NCI clinical trial networks or NCI grants (R01, SP0RES, etc)
 - Covers comprehensive profiling for approximately 400 patient–timepoint per year
- **Utilization of the CIMAC-CIDC resource is voluntary, but desired studies will require collaboration with CIMAC and approval by CTEP.**

Awardees

CIMACs

- **Dana-Farber Cancer Institute**
PIs: Catherine Wu and F. Stephen Hodi
- **The University of Texas MD Anderson Cancer Center**
PIs: Ignacio Wistuba, Elizabeth Mittendorf, Chantale Bernatchez
- **Icahn School of Medicine at Mount Sinai**
PI: Gnjjatic Sacha
- **Stanford University (Pediatric)**
PIs: Holden Maecker, Sean Bendall

CIDC

- **Dana-Farber Cancer Institute**
PIs: Xiaole Shirley Liu, Ethan Cerami

Proposed CIMACs-CIDC Network Structure (Tentative)

A more comprehensive slide deck is now posted on the SWOG Website and last week's "Link of the week" email from HQ!

AND you can bring your usb drive to Hope Foundation Desk and download slides here

- Assay expertise or resource prioritization
- Overall workload or Established relationship with specific trials
- Other factors

Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment (U01)

RFA-CA-17-029, due date January 23, 2018

The purpose of this initiative is to establish an **Academic-Industrial Partnership Program** to develop new and/or validate existing technologies, methods, and assays for the capture and quantification of tumor associated cells, DNA, RNA, or exosomes in body fluids of patients with early stage disease or those at high risk; as well as distinguishing cancer from benign disease; or aggressive from indolent cancers. The precompetitive alliances with industry will harmonize and validate technologies, methods and assays associated with liquid biopsies.

Plenary 1: Translational Medicine

3:15 - 3:45 pm

Harnessing the Power of Genomics in Correlative Studies

Elaine Mardis, Ph.D.

Nationwide Foundation Endowed Chair in Genomic Medicine

Co-Executive Director, Institute for Genomic Medicine

Ohio State University College of Medicine, Nationwide Children's Hospital

3:35 – 4:00 pm

Liquid Biopsies...What's Next?

Luis Diaz, Jr., M.D.

Head, Division of Solid Tumor Oncology

Department of Medicine

Memorial Sloan Kettering Cancer Center

3:45 - 4:15 pm

The SWOG Biospecimen Bank: Investing in the Future of Translational Research

Nilsa C. Ramirez, M.D.

Medical Director, Biopathology Center, Director, Surgical Pathology

Lead Pathologist, Biospecimen Core Resource

Associate Professor, The Ohio State University College of Medicine

Nationwide Children's Hospital